MoneyWorks4Me

Medicamen Biotech reports Profit after tax of Rs 42.22 Mln, in the September 2021 quarter

03 Nov 2021 Evaluate
The September 2021 quarter revenue stood at Rs. 325.20 millions, up 5.68% as compared to Rs. 307.72 millions during the corresponding quarter last year.An average growth of 30.96% was recorded for the quarter ended September 2021 to Rs. 42.22  millions from Rs. 32.24 millions.Operating profit surged to 67.03 millions from the corresponding previous quarter of 56.77 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 325.20 307.72 5.68 600.50 568.87 5.56 1101.46 1173.42 -6.13
Other Income 4.76 1.32 260.61 5.55 2.16 156.94 7.54 19.09 -60.50
PBIDT 67.03 56.77 18.07 128.22 96.62 32.71 203.35 196.71 3.38
Interest 3.00 3.78 -20.63 3.44 6.18 -44.34 10.64 5.68 87.32
PBDT 64.03 52.99 20.83 124.78 90.44 37.97 192.71 191.03 0.88
Depreciation 13.50 6.99 93.13 26.80 13.91 92.67 25.20 24.99 0.84
PBT 50.53 46.00 9.85 97.98 76.53 28.03 167.51 166.04 0.89
TAX 8.31 13.76 -39.61 14.25 23.24 -38.68 42.65 43.45 -1.84
Deferred Tax -3.99 0.16 -2593.75 -4.65 0.41 -1234.15 1.19 -2.50 -147.60
PAT 42.22 32.24 30.96 83.73 53.29 57.12 124.86 122.59 1.85
Equity 122.17 122.17 0.00 122.17 122.17 0.00 122.17 122.17 0.00
PBIDTM(%) 20.61 18.45 11.73 21.35 16.98 25.72 18.46 16.76 10.13
Peers
Company Name CMP
Sun Pharma. Inds. 1853.00
Dr. Reddys Labs. 1200.40
Cipla 1404.00
Lupin 2098.00
Zydus Lifesciences 1180.00
View more..